First of all, we need more clinicians who have the right training and skills to conduct psychedelic-assisted therapies and prescribe those medicines. I think the nature of the program does pose barriers to people who may be marginalized, who may have fewer resources and who may not have access to psychiatrists. If they do, they may not have the type of relationship they need in order to feel they can trust those providers.
We really need to do a deep dive and look at the demographics of the people who are accessing this program, including racial and ethnic demographics, to ensure that it's being rolled out equitably. To my knowledge, this information isn't really being collected in a systemic way, so that would make it really hard to say conclusively who this program is benefiting and who it isn't.